Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]

read more

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]

read more

Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more

Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer

The results from the renal cell carcinoma (RCC) group of patients in a phase 1b/2 trial of a combination of lenvatinib plus pembrolizumab were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In this study, 30 patients with metastatic clear cell RCC were treated with oral lenvatinib […]

read more

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in New York discussed the past, present and future of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) for the treatment of advanced/metastatic renal cell carcinoma […]

read more

Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

The US Food and Drug Administration (FDA) have granted Breakthrough Therapy Designation for the multiple receptor tyrosine kinase inhibitor, lenvatinib (Kisplyx) in combination with the anti-PD-1 therapy, pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC). The breakthrough therapy designation speeds up the development and review of medicines that […]

read more

Sequencing of treatments for advanced kidney cancer remains uncertain

There are now a number of licensed drug options available for the treatment of advanced renal cell carcinoma (RCC). Many of them have data supporting their use as first- and second-line treatments. However, it is still not clear what sequence these drugs should be used in, especially as data coming out of clinical trials may […]

read more

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

Fantastic news for people with advanced kidney cancer: the lenvatinib (Kisplyx) plus everolimus (Afinitor) combination has been recommended by the National Institute for Health and Care Excellence (NICE) for use by the NHS in England and Wales for people with advanced renal cell carcinoma (RCC) that has been previously treated. This is the first combination of treatments to be […]

read more

The evolving management of advanced renal cell carcinoma

This article, published in UroToday this week, is a nice summary of the latest treatments available or in development for clear cell renal cell carcinoma and non-clear cell renal cell carcinoma. Read the article in UroToday here

read more
Showing 1 to 10 of 20 results
  TOP